Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR0832)
Name
Megestrol acetate
Synonyms
MEGESTROL ACETATE; 595-33-5; Megace; Megace ES; Magestin; Niagestin; Megestryl acetate; Megeron; Megestat; Ovaban; Ovarid; Maygace; Pallace; BDH 1298; SC 10363; NSC-71423; Volidan; SC10363; UNII-TJ2M0FR8ES; 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; 17alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate; 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate; TJ2M0FR8ES; [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate; 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate; SC-10363; 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione; MLS000028633; Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-; BDH-1298; SMR000058691; DSSTox_CID_20683; DSSTox_RID_79539; DSSTox_GSID_40683; Megestil; 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione; Ovaban (Veterinary); 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone; MegestrolAcetate; 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate; Megestrol-Acetate; 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate; CCRIS 372; Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate; Megestrol-17-acetate; EINECS 209-864-5; Megestin; Megestrol acetole [Progestins]; Megestrol acetate [USAN:USP]; Megestrol acetole; BDH1298; 17-alpha-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone; 6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone; NCGC00016516-01; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; CAS-595-33-5; Megace (TN); 17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione; 6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate; 6-Methyl-6-dehydro-17.alpha.-acetylprogesterone; 6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone; 6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate; 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone; 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone; 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone; Megestrol acetate (USP); Opera_ID_1511; Prestwick0_000956; Prestwick1_000956; Prestwick2_000956; Prestwick3_000956; 6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate; SCHEMBL745; BSPBio_000952; MLS000759501; MLS001074091; MLS001424055; par-100,2; SPBio_003101; BPBio1_001048; CHEBI:6723; CHEMBL1201139; DTXSID9040683; BCPP000168; HMS1570P14; HMS2051I20; HMS2090N04; HMS2097P14; HMS2235D16; HMS3714P14; Nia; NSC71423; ZINC4097467; Tox21_110469; Tox21_302360; ANW-43468; LMST02030118; MFCD00056470; s1304; AKOS015894927; Tox21_110469_1; BCP9000904; CCG-100899; CS-2065; DB00351; NC00149; 17-Acetoxy-6-methylpregna-4,20-dione; NCGC00024196-03; NCGC00024196-05; NCGC00255456-01; AC-24570; AS-13384; HY-13676; I040; 17.alpha.-Acetoxy-6-methyl-4,20-dione; AB00490013; B1377; 17-Hydroxy-6-methylpregna-4,20-dione acetate; 17.alpha.-Acetoxy-6-methylpregna-4,20-dione; C08151; D00952; 14365-EP2311464A1; 14365-EP2316836A1; AB00383046-13; AB00383046-14; AB00383046-15; AB00383046_16; Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-; 595M335; SR-01000000258; Megestrol-17-acetate 100 microg/mL in Acetonitrile; Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate; Q-201346; Q6808975; SR-01000000258-4; BRD-K19507340-001-03-1; Megestrol acetate, VETRANAL(TM), analytical standard; 17alpha-Acetoxy-6-methyl-4,6-pregnadiene-3,20-dione; Megestrol acetate, analytical standard, for drug analysis; WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1; 6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate; Megestrol acetate, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate, United States Pharmacopeia (USP) Reference Standard; Megesgtrol Acetate, Pharmaceutical Secondary Standard; Certified Reference Material; Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard; Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard
    Click to Show/Hide
Molecular Type
Small molecule
Disease Cancer cachexia [ICD-11: MG20] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C24H32O4
PubChem CID
11683
Canonical SMILES
CC1=CC2C(CCC3(C2CCC3(C(=O)C)OC(=O)C)C)C4(C1=CC(=O)CC4)C
InChI
1S/C24H32O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h12-13,18-20H,6-11H2,1-5H3/t18-,19+,20+,22-,23+,24+/m1/s1
InChIKey
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
CAS Number
CAS 595-33-5
ChEBI ID
CHEBI:6723
DrugBank ID
DB00351
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Arsenic trioxide      Realgar and orpiment     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation ERK1  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation ERK2  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation JNK1  Molecule Info 
Pathway MAP
Up-regulation Phosphorylation p38 beta  Molecule Info 
Pathway MAP
Up-regulation Cleavage PARP1  Molecule Info 
Pathway MAP
                    In-vitro Model Hep-G2 CVCL_0027 Hepatocellular carcinoma Homo sapiens
BEL-7402 CVCL_5492 Human hepatocellular carcinoma Homo sapiens
                    In-vivo Model HepG2 cells were collected in 0.2 ml of PBS, and the cell suspensions were then injected subcutaneously into five-week-old BALB/C male nude mice (5*106 cells per mouse).
                    Experimental
                    Result(s)
MA/ATO combined treatment enhanced antitumor efficacy.
Target and Pathway
Target(s) Glucocorticoid receptor (NR3C1)  Molecule Info  [3]
Progesterone receptor (PGR)  Molecule Info  [4]
KEGG Pathway Neuroactive ligand-receptor interaction Click to Show/Hide
2 Oocyte meiosis
3 Progesterone-mediated oocyte maturation
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 TCR Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Signaling events mediated by HDAC Class II
3 FOXA2 and FOXA3 transcription factor networks
4 Glucocorticoid receptor regulatory network
5 Regulation of Androgen receptor activity
6 AP-1 transcription factor network
7 Cellular roles of Anthrax toxin
Reactome BMAL1:CLOCK,NPAS2 activates circadian gene expression Click to Show/Hide
2 Nuclear signaling by ERBB4
3 Nuclear Receptor transcription pathway
WikiPathways Serotonin Receptor 4/6/7 and NR3C Signaling Click to Show/Hide
2 SIDS Susceptibility Pathways
3 Nuclear Receptors Meta-Pathway
4 Endoderm Differentiation
5 Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
6 Adipogenesis
7 Circadian Clock
8 Nuclear Receptors
9 Ovarian Infertility Genes
10 Signaling by ERBB4
References
Reference 1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2014
Reference 2 Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells. Exp Ther Med. 2018 Apr;15(4):4047-4055.
Reference 3 Megestrol Acetate Increases the Proliferation, Migration, and Adipogenic Differentiation of Adipose-Derived Stem Cells via Glucocorticoid Receptor. Stem Cells Transl Med. 2015 Jul;4(7):789-99.
Reference 4 Megestrol acetate drives endometrial carcinoma cell senescence via interacting with progesterone receptor B/FOXO1 axis. Exp Biol Med (Maywood). 2021 Jul 7:15353702211026566.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China